Business Segments · Consolidated revenues
Specialty Diagnostics — Consolidated revenues
Thermo Fisher Scientific Specialty Diagnostics — Consolidated revenues decreased by 89.6% to $1.14B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 89.0%, from $10.36B to $1.14B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026May 1, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong market demand and successful product adoption, while a decrease signals market saturation or competitive pressure.
Detailed definition
The total gross income generated from the sale of diagnostic products, reagents, and services within the Specialty Diagn...
Peer comparison
Key performance indicator for all diagnostic equipment and consumable manufacturers.
Metric ID:
tmo_segment_specialty_diagnostics_consolidated_revenuesHistorical Data
37 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.27B | $1.24B | $9.33B | $1.36B | $10.7B | $1.45B | $11.82B | $1.48B | $10.97B | $1.1B | $10.68B | $1.07B | $11.45B | $1.12B | $10.71B | $1.11B | $10.69B | $1.11B | $10.57B | $1.08B | $10.89B | $1.11B | $10.35B | $1.11B | $10.54B | $1.12B | $10.6B | $1.13B | $11.4B | $1.16B | $10.36B | $1.15B | $1.13B | $1.17B | $1.22B | $11.01B | $1.14B |
| QoQ Change | — | -86.7% | +655.5% | -85.4% | +685.8% | -86.5% | +716.7% | -87.5% | +640.2% | -90.0% | +869.8% | -90.0% | +975.1% | -90.3% | +860.5% | -89.7% | +864.5% | -89.6% | +853.5% | -89.8% | +905.2% | -89.8% | +836.2% | -89.3% | +850.5% | -89.4% | +848.8% | -89.3% | +909.3% | -89.8% | +795.8% | -88.9% | -1.2% | +3.5% | +3.9% | +802.0% | -89.6% |
| YoY Change | — | — | — | — | — | — | — | — | +18.3% | -88.1% | +14.4% | -88.6% | +7.0% | -89.6% | -9.4% | -90.6% | -2.6% | -89.9% | -1.0% | -89.9% | -4.9% | -90.3% | -3.4% | -89.6% | -1.4% | -89.5% | +0.2% | -89.3% | +4.7% | -89.4% | +0.2% | -88.9% | -89.2% | -88.9% | -89.3% | +6.2% | -89.0% |
Range$1.07B – $11.82B
CAGR-20.8%
Avg YoY Growth-48.3%
Median YoY Growth-88.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's specialty diagnostics — consolidated revenues?
- Thermo Fisher Scientific (TMO) reported specialty diagnostics — consolidated revenues of $1.14B in Q1 2026.
- How has Thermo Fisher Scientific's specialty diagnostics — consolidated revenues changed year-over-year?
- Thermo Fisher Scientific's specialty diagnostics — consolidated revenues decreased by 89.0% year-over-year, from $10.36B to $1.14B.
- What does specialty diagnostics — consolidated revenues mean?
- Total sales generated by the Specialty Diagnostics business segment.